Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Hologic, Inc.

78.5% sales growth and 46.05% return on equity

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, surgical products, and light-based aesthetic and medical treatment systems for women in the United States and internationally.

Hologic, Inc.’s sales growth this year is expected to be 35.9% and a negative 16.5% for next year.

Year-on-year quarterly revenue growth grew by 55.5%, now sitting on 3.78B for the twelve trailing months.

Hologic, Inc.’s sales growth is a negative 0% for the ongoing quarter and 78.5% for the next. The company’s growth estimates for the present quarter and the next is 250.8% and 252.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.05%.

Volatility

Hologic, Inc.’s last day, last week, and last month’s average volatility was 3.23%, 2.03%, and 0.49%, respectively.

Hologic, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.74%, 4.48%, and 3.51%, respectively.

Hologic, Inc.’s Stock Yearly Top and Bottom Value

Hologic, Inc.’s stock is valued at $80.49 at 10:22 EST, below its 52-week high of $81.80 and way above its 52-week low of $26.49.

Hologic, Inc.’s Moving Average

Hologic, Inc.’s value is above its 50-day moving average of $73.27 and way higher than its 200-day moving average of $66.95.

2. Qualys, Inc.

12.4% sales growth and 23.23% return on equity

Qualys, Inc. provides cloud-based platform that delivers information technology (IT), security, and compliance solutions in the United States and internationally.

Qualys, Inc.’s sales growth this year is expected to be 12.8% and 12.5% for next year.

Year-on-year quarterly revenue growth grew by 12.6%, now sitting on 352.83M for the twelve trailing months.

Qualys, Inc.’s sales growth for the next quarter is 12.4%. The company’s growth estimates for the present quarter and the next is 9.4% and 6.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.23%.

Volatility

Qualys, Inc.’s last day, last week, and last month’s average volatility was a negative 0.33%, a positive 1.04%, and a positive 1.40%, respectively.

Qualys, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 4.93%, 4.09%, and 5.26%, respectively.

Qualys, Inc.’s Stock Yearly Top and Bottom Value

Qualys, Inc.’s stock is valued at $121.78 at 10:22 EST, under its 52-week high of $126.30 and way above its 52-week low of $63.37.

Qualys, Inc.’s Moving Average

Qualys, Inc.’s value is way above its 50-day moving average of $106.48 and way above its 200-day moving average of $103.58.

3. Collegium Pharmaceutical, Inc.

10.4% sales growth and 13.69% return on equity

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain.

Collegium Pharmaceutical, Inc.’s sales growth this year is anticipated to be 5.1% and 8.9% for next year.

Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 307.95M for the twelve trailing months.

Collegium Pharmaceutical, Inc.’s sales growth for the next quarter is 10.4%. The company’s growth estimates for the current quarter and the next is 542.9% and 3600%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.69%.

Volatility

Collegium Pharmaceutical, Inc.’s last day, last week, and last month’s average volatility was 1.84%, 2.39%, and 0.63%, respectively.

Collegium Pharmaceutical, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.93%, 7.36%, and 5.31%, respectively.

Collegium Pharmaceutical, Inc.’s Stock Yearly Top and Bottom Value

Collegium Pharmaceutical, Inc.’s stock is valued at $21.83 at 10:22 EST, way under its 52-week high of $25.59 and way above its 52-week low of $13.00.

Collegium Pharmaceutical, Inc.’s Moving Average

Collegium Pharmaceutical, Inc.’s worth is way above its 50-day moving average of $19.53 and way higher than its 200-day moving average of $18.88.

4. Grand Canyon Education, Inc.

6.2% sales growth and 17.03% return on equity

Grand Canyon Education, Inc. provides education services to colleges and universities in the United States.

Grand Canyon Education, Inc.’s sales growth this year is expected to be 8.1% and 9.8% for next year.

Year-on-year quarterly revenue growth grew by 2.6%, now sitting on 819.05M for the twelve trailing months.

Grand Canyon Education, Inc.’s sales growth for the next quarter is 6.2%. The company’s growth estimates for the current quarter and the next is 9.2% and 7.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.03%.

Volatility

Grand Canyon Education, Inc.’s last day, last week, and last month’s average volatility was a positive 1.12%, a negative 0.40%, and a positive 0.19%, respectively.

Grand Canyon Education, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.16%, 3.02%, and 2.81%, respectively.

Grand Canyon Education, Inc.’s Stock Yearly Top and Bottom Value

Grand Canyon Education, Inc.’s stock is valued at $91.04 at 10:22 EST, way below its 52-week high of $106.14 and way above its 52-week low of $57.89.

Grand Canyon Education, Inc.’s Moving Average

Grand Canyon Education, Inc.’s value is above its 50-day moving average of $89.94 and higher than its 200-day moving average of $88.10.

LEAVE A REPLY

Please enter your comment!
Please enter your name here